Clinical Trials · NCT06461910
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Zekuan Xu
- Enrollment
- 30
- Start date
- Jun 2024
- Locations
- 1 site, China
- Primary endpoint
- pathological Complete Response (pCR)